StockpollyBeta
Get App
Popularity #651
JAZZ · NASDAQ · Biotechnology

Jazz Pharmaceuticals (JAZZ)

Develops rare-disease medicines across sleep, epilepsy and oncology.

$241.07
vs last close−0.39 (−0.16%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue9721,0129021,0241,0551,0888981,0461,1261,1981,0691,208
Cost of revenue1021079511011212910511625825306116
Gross profit8709058069149439597939298681,1737631,092
6987827407146837698491,616811264549844
Research & development234217223221200241181190241171134208
Selling, general & administrative308396352339326369514358531406353389
Other expenses1551701661551571591541,06739−31462247
Operating income17212266199260191−56−68658909214248
−73−61−69−62−60−58−54−49−48−70185−37
Interest income0000000000230
Interest expense717066625951544749456337
Other non-operating income0−112−3901−38−3020656−1490
Income before tax10061−3138201133−110−7369208299211
Income tax expense−47−3312−31−15−58−18−17−2425618
Net income from continuing operations14794−15169215191−93−718251203293193
Other adjustments000000000000
Net income14794−15169215191−93−718251203293193
EPS, basic$2.33$1.50−$0.23$2.68$3.50$3.16−$1.52−$11.74$4.14$3.28$4.73$3.05
EPS, diluted$2.14$1.42−$0.23$2.49$3.42$3.11−$1.52−$11.74$4.08$3.34$4.43$2.78
Weighted average shares, basic636363636161616161616263
Weighted average shares, diluted717063706362616162616669
EBITDA335394269363424397139−514236279544418
Depreciation & amortization16315916316316516816517417825181170
EBIT172235105200259229−26−68858254363248